Epilepsia and paroxyzmal conditions

Advanced search


Full Text:


Antiepileptic drugs are frequently associated with a risk of adverse effects,  which have an impact on the tolerability and success of treatment. Patients who develop intolerable adverse effects have to discontinue treatment early after initiation or to switch to another antiepileptic drug. A long-term management  strategy for the patients with such a long-lasting chronic disease  as epilepsy should include both effective  seizure control and early detection  of adverse drug events, ensuring prognosis, prevention and minimizing side effects,  which is quite important. All these measures  are expected to improve adherence to treatment, quality of patients’ life and control of epilepsy.

About the Author

I. Yu. Kovaleva
N. I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation

Kovaleva Irina Jur’evna – MD, PhD, Professor  in the Department of Neurology, Neurosurgery and Medical Genetics at Medical Faculty.

1 Ostrovityanova str., Moscow, 117997


1. Voronkova K. V., Petrukhin A. S. et al. Rational antiepileptic therapy [Ratsional’naya antiepilepticheskaya terapiya (in Russian)]. Moscow. 2008; 191 s.

2. Karlov V. A. Epilepsy in children and adult men and women. Guide for physicians [Epilepsiya u detei i vzroslykh muzhchin i zhenshchin Rukovodstvo dlya vrachei (in Russian)]. Moscow. 2010; 718 s.

3. Banerjee P. N., Filippi D., Hauser W. A. The descriptive epidemiology of epilepsu:a review. Epilepsia. 2009; 85 (1): 31-45.

4. Joannessen Landmark C., Larsson P. G. et al. Antiepileptic drugs in epilepsy and other disoders: a population-based study of prescriptions. Epilepsy Res. 2009; 87 (1): 31-9.

5. Gusev E. I., Belousov Yu.B., Gekht A. B. et al. Treatment of epilepsy: rational dosing of anticonvulsants [Lechenie epilepsii: ratsional’noe dozirovanie antikonvul’santov (in Russian)]. SPb. 2000; 201 s.

6. Zenkov L. R. Anticonvulsant therapy may aggravate the course of epilepsy. Nevrologicheskii zhurnal. 2007; 12 (3): 8-13.

7. Mukhin K. Yu., Petrukhin A. S., Rykova E. A. Adverse effects of anticonvulsants in treatment of idiopathic generalized epilepsy. Zhurnal nevrologii i psikhiatrii. 1997; 7: 25-31.

8. Perucca E. Adverse ef fect of antiepileptic drugs. Focus Farmacovigilanza. 2012; 80 (1): 1.

9. Perucca E. et al. Adverse antiepileptic drug effects: Toward a clinically and neurobiologically relevant taxonomy. Neurology. 2009; 72: 1223-1229.

10. Baker G. A., Middleton A., Jacoby A. et al. Initial development, reliability, and validity of a patient-based adverse event scale. Epilepsia. 1994; 35 (7): 80.

11. Schmitz B., Robertson M., Trimble M. R. Depression and schizophrenia in epilepsy: social and biological risk factors. Epilepsy Res. 1999; 35: 59-68.

12. Herranz J. L., Armijo J. A., Arteaga R. Clinical side effects of phenobarbital, primidon, phenytoin, carbamazepine and valproate in children. Epilepsia. 1988; 29 (6): 794-804.

13. Rosenfield R. L. Clinical practice: hirsuitism. N Engl J Med. 2005; 353 (24): 2578-88.

14. Smith M. C., Centorino F. et al. Clinical comparison of extended-release divaproex versus delaed-release divaproex: pooled data analysis from nine trials. Epilepsy Behav. 2004; 5 (5): 746-51.

15. Koch-Weser J., Browne T. R. Drug therapy: valproic acid. N Engl J Med. 1980; 302 (12): 661-6.

16. Shapiro J. Clinical practice: hair loss in women. N Engl J Med. 2017; 3579160: 1620-30.

17. Tengstrand M et al. Allopecia in association with lamotrigine use: analisis of individual case safety reports in a global database. Drug Saf. 2010; 33 (8): 653-8.

18. Aarli J. A. Phenitoin-induced depression of salivation IgA gingival hyperplasia. Epilepsia. 1976; 17 (3): 283-91.

19. Cerminara C. et al. Hipohydrosis during topiramate treatment: a rare and reversible side effect. Pediatr Neurol. 2006; 34 (5): 392-4.

20. Leppic I. E. Practical prescribing and long-term efficacy and safety of zonisamid. Epilepsia. 2006; 68 (2): 17-24.

21. FDA Safety Communication UCM349847, 24/04/2013.

22. Beniczky S. A., Viken J. et al. Bone mineral density in adult patients treated with various AEDs. Seizure. 2012; 21 (6): 471-2.

23. Ali I. I., Herial N. A. et al. Measurement of bone minerals density in patient on levetiracetam monotherapy. Epilepsia. 2006; 47 (4): 276.

24. Koo D. L., Yoo E. I. et al. Effect of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patient with epilepsy. Epilepsy Res. 2013; 104 (1-2): 134-9.

25. DeToledo J.C., Toledo C. et al. Changes in body weight with chronic, high-dose gabapentine therapy. Ther Drug Monit.1997; 19 (4): 394-6.

26. Arroyo S., Anhut H. et al. Pregabaline add-on treatment: a randomized, doubleblind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia. 2004; 45910: 20-7.

27. Ben-Menachem E. Weight issues for people with epilepsy: a review. Epilepsia. 2007; 48 (9): 42-5.

28. Jallon P., Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug saf. 2001; 24 (13): 969-78.

29. Biton V., Mirza W. et al. Weigh change association with valproate and lamotrigine in patient with epilepsy. Neurology. 2001; 56 (2): 172-7.

30. Freitag F. G., Collins S. D. et al. A randomize trial of divalproex sodium extended-release tablets in migrain prophilaxis. Neirology. 2002; 58 (11): 1652-9.

31. Privitera M. D., Brodie M. J. et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand. 2003; 107 (3): 165-75.

32. Uludag I. F., Kulu U., Sner U. et al. The effect of carbamazepine treatment on serum leptin levels. Epilepsy Res. 2009; 86 (1): 48-53.

33. Bromley R. L., Leeman B. A., Baker G. A. et al. Cognitive and neurodevelopmental effects of antiepileptic drugs. Epilepsy Behav. 2011; 22 (1): 9-16.

34. Verrotti A., Scaparotta A. et al. Topiramateinduced weight loss: a review. Epilepsy Res. 2011; 95 (3): 189-99.

35. Ben-Menachem E., Axelsen M. et al. Predictors of weight loss in adults with topiramat-treated epilepsy. Obes Res. 2003; 11 (4): 556-62.

36. Eiris J., Novo-Rodriguetz M.I. et al. The effects on lipid and apolipoprotein serum levels on long-term carbamazepine: valproic acide and phenobarbital therapy in children with epilepsy. Epilepsy Res. 2004; 41 (1): 1-7.

37. Galimberti C. A. et al. Changes in sex steroid level in women with epilepsy on treatment. 2009.

38. Verotti A et al. Antiepileptic drugs, sex hormones and PCOS. 2011; 52 (2): 199-211.

39. Isojarvi J. Disoders of reproduction in patients with epilepsy: antiepileptic drug related mechanisms. 2008.

40. Brodie M. J. et al. Enzyme induction with antiepileptic drugs: cause for concern? 2013.

41. Gaitatzis A., Sander J. W. The long-term safety of antiepileptic drugs. CNS Drugs. 2013; 27: 435-455.

42. Matsuura M. Epileptic psychoses and anticonvulsant drug treatment. J Neurol Neurosurg Psychiatry. 1999; 67: 231-3.

43. Mula M., Argawal A., et al. Self-reported aggressiveness during treatment with LEV correlates with depression. 2015.

44. Panelli R. J. et al. The Liverpool adverse events profile: relation to AED use and mood. Epilepsia. 2007; 48 (3); 456-463.

45. Brodie M. J., Covanis A., Gil-Nagel A. et al. Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav. 2011; 21 (4): 331-41.

46. Eddy C. M., Rickards H. E., Cavanna A. E. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord. 2011; 4 (6): 385-407.

47. Riss J., Cloyd J., Gates J. et al. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008; 118 (2): 69-86.

48. Meador K. J., Loring O. W., Moore E. E. et al. Comparative cognitive effects of phenobarbital, phenytoin, and valproate in healthy adults. Neurology. 1995; 45 (8): 1494-9.

49. Farwell J. R., Lee Y. J., Hirtz D. G. et al. Phenobarbital for febrile seizures: effects on intelligence and on seizure recurrence. N Engl J Med. 1990; 322 (6): 364-9.

50. Arif H., Buchsbaum R., Weintraub D., et al. Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy Behav. 2009; 14 (1): 202-9.

51. White J. R., Walczak T. S., Marino S. E. et al. Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study. Neurology. 2010; 75 (6): 513-8.

52. Bootsma H. P., Vos A. M., Hulsman J. et al. Lamotrigine in clinical practice: long-tenn experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav. 2008; 12 (2): 262-8.

53. Marino S. E., Meador K. J., Loring O. W. et al. Subjective perception of cognition is related to mood and not performance. Epilepsy Behav. 2009; 14 (3): 459-64.

54. Luef G., Rauchenzauner M., Waldmann M. et al. Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res. 2009; 86 (1):42-7.

55. Verrotti A., Agostinelli S., Parisi P. et al. Nonalcoholic fatty liver disease in adolescents receiving valproic acid. Epilepsy Behav. 2011; 20 (2): 382-5.

56. Pellock J. M. Felbamate. Epilepsia. 1999; 40(5): 57-2.

57. Koenig S. A., Buesing D., Longin E. et al. Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia. 2006; 47 (12): 2027-31.

58. Gram L., Bentsen K. D. Hepatic toxicity of antiepileptic drugs: a review. Acta Neurol Scand Suppl. 1983; 97: 81-90.

59. E. Björnsson. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand. 2008; 118: 281-290.

60. Binek J., Hany A., Heer M. Valproic-acidinduced pancreatitis: case report and review of the literature. J Clin Gastroenterol. 1991; 13 (6): 690-6.

61. Pellock J. M., Wilder B. J., Deaton R. et al. Acute pancreatitis coincident with valproate use: a critical review. Epilepsia. 2002; 43 (11): 1421-4.

62. Asconape J. J., Penry J. K., Dreifuss F. E. et al. Valproate-associated pancreatitis. Epilepsia. 1993; 34 (1): 177-83.

63. Buggy Y., Layton D., Fogg C. et al. Safety profile of oxcarbazepine: results from a prescription-event monitoring study. Epilepsia. 2010; 51 (5): 818-29.

64. Letmaier M., Painold A., Holl A. K. et al. Hyponatriaemia during psychopharmacological treatment: results of a drug surveillance progrartune. Int J Neuropsychopharmacol. 2012; 15 (6): 739-48.

65. Dong X., Leppik T. E., White J. et al. Hyponatremia from oxcarbazepine and carbamazepine. Neurology. 2005; 65 (12): 1976-8.

66. Neligan A. et al. The long-term risk of premature mortality in people with epilepsy. Brain. 2011.

67. Bardai A. et al. Sudden cardiac death in associated both with epilepsy and with use of AED. Heart. 2014; 1-6.

68. Weig SG, Pollack P. Carbamazepine-induced heart block in a child with tuberous sclerosis and cardiac rhabdomyoma: implications for evaluation and follow-up. Ann Neurol. 1993; 34 (4): 617-9.

69. DeGiorgio C. M. Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures. Epilepsy Behav. 2010; 18 (3): 322-4.

70. Zaccara G., Perucca P., Loiacono G. et al. The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2013; 54 (1): 66-74.

71. Danielsson B. R., Lansdell K., Patmore L. et al. Phenytoin and phenobarbital inhibit human HERG potassium channels. Epilepsy Res. 2003; 55 (1-2): 147-57.

72. Danielsson B. R., Lansdell K., Patmore L. et al. Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on bERG potassium currents. Epilepsy Res. 2005; 63 (1): 17-25.

73. Schimpf R., Veltrnann C., Papavassiliu T. et al. Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide. Heart Rhythm. 2012; 9 (5): 776-81.

74. Brodie M. J., Sills G. J., Combining antiepileptic drugsm – Rational polytherapy. Seizure. 2011; 20: 369-375.

75. French J. A. Antiepileptic drug treatment. Continuum, Lifelong learning in neurology. Epilepsy. 2013; 643-656.

76. Runge U., Arnold S., Brandt C. et al. A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: VITIBA study. Epilepsia. 2015; 56 (12): 1921-1930.

For citation:

Kovaleva I.Y. ADVERSE EFFECTS OF ANTIEPILEPTIC DRUGS. Epilepsia and paroxyzmal conditions. 2017;9(1):51-61. (In Russ.)

Views: 353

ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)